Valuation: UCB

Market Cap 40.4B 46.04B 38.16B 34.77B 65.09B 4,413B 65.56B 457B 177B 2,254B 173B 169B 7,245B P/E 2026 *
21.2x
P/E 2027 * 17.6x
Enterprise Value 40.8B 46.5B 38.53B 35.12B 65.74B 4,456B 66.21B 461B 179B 2,277B 175B 171B 7,317B EV / Sales 2026 *
4.7x
EV / Sales 2027 * 4.02x
Free-Float
61.59%
Yield 2026 *
0.69%
Yield 2027 * 0.71%
1 day+3.12%
1 week-1.32%
Current month-2.79%
1 month-8.78%
3 months-15.44%
6 months-17.66%
Current year-16.93%
1 week 230.16
Extreme 230.16
252.34
1 month 228.94
Extreme 228.94
268.09
Current year 228.94
Extreme 228.94
345.39
1 year 225.65
Extreme 225.65
345.39
3 years 69.7
Extreme 69.7
345.39
5 years 68.3
Extreme 68.301062
345.39
10 years 58.42
Extreme 58.42
345.39
Manager TitleAgeSince
Chief Executive Officer 67 31/12/2014
Director of Finance/CFO 60 30/06/2020
Chief Tech/Sci/R&D Officer 59 30/04/2024
Director TitleAgeSince
Director/Board Member 55 31/12/2011
Director/Board Member 67 31/12/2014
Director/Board Member 56 23/04/2014
Change 5-day change 1-year change 3-year change Capi.($)
+3.12%-1.32% - - 45.93B
-0.95%+0.25%+41.63%-5.73% 79.49B
+1.56%+28.39%+703.64%+101.46% 77.78B
-1.21%-0.34%-10.33%-29.82% 60.16B
-1.80%-2.15%-15.06%+26.38% 46.14B
+1.18%+3.03%+9.11%+169.01% 45.93B
+0.08%+5.38%+67.38%-10.95% 33.45B
-0.41%-1.26%+51.52%+110.61% 25.22B
-0.10%+3.69%+4.89%+166.22% 22.15B
+0.05%-2.42%+57.59%+97.38% 15.25B
Average +0.14%+2.98%+101.15%+69.39% 45.06B
Weighted average by Cap. +0.16%+4.93%+152.08%+54.77%

Financials

2026 *2027 *
Net sales 8.68B 9.89B 8.2B 7.47B 13.99B 948B 14.09B 98.13B 38.01B 484B 37.15B 36.35B 1,557B 9.62B 10.97B 9.09B 8.28B 15.5B 1,051B 15.61B 109B 42.12B 537B 41.17B 40.28B 1,726B
Net income 1.93B 2.2B 1.82B 1.66B 3.11B 211B 3.13B 21.79B 8.44B 108B 8.25B 8.07B 346B 2.3B 2.62B 2.17B 1.98B 3.7B 251B 3.73B 25.95B 10.05B 128B 9.83B 9.61B 412B
Net Debt 399M 455M 377M 343M 643M 43.58B 647M 4.51B 1.75B 22.27B 1.71B 1.67B 71.56B -1.73B -1.97B -1.63B -1.49B -2.78B -189B -2.8B -19.52B -7.56B -96.36B -7.39B -7.23B -310B
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
24/09/26 US$243.88 +3.12% 543
22/09/26 US$236.49 +1.12% 379
21/09/26 US$233.86 -6.65% 429
18/09/26 US$250.52 +1.37% 31
17/09/26 US$247.14 -0.39% 37
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
211.90EUR
Average target price
285.00EUR
Spread / Average Target
+34.50%

Quarterly revenue - Rate of surprise